Upstream & Downstream Processing

Scancell adds first partner for high potent MAb tech

Immuno-oncology firm Scancell has begun offering its AvidiMab technology to partners looking to increase the potency of their monoclonal antibody pipelines. Scancell has its own pipeline of monoclonal antibodies (MAbs) targeting novel cancer treatments, but this deal represents the first collaboration with an external partnerover its AvidiMab technology. “AvidiMab is proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumor killing of antibodies directed to tumor associated antigens (TaGs) but may…

ABEC breaks plastic ceiling again with 6,000 L single-use bioreactor

ABEC has launched a single-use bioreactor system with a working volume of 6,000 L – three times that of industry’s standard upper limit. While single-use bioreactors are a staple in the industry these days, one of the commonly discussed limitations of such systems in a commercial setting are their size. Most vendors offer bioreactors of 2,000 L as their upper limit leaving biomanufacturers to either run several systems in unison or opt for stainless-steel tanks if requiring larger volumes. But…

MilliporeSigma buys data platform to bolster its Biopharma 4.0 offering

MilliporeSigma has bought the rights to the ProcessPad platform from Simplyfeye Softwares, adding the latest “building block” to its BioContinuum Platform. The ProcessPad platform from Simplyfeye Softwares Private Limited brings MilliporeSigma a data management and analytics solution capable of capturing development, scale-up, commercial and process data on a single platform as well as analyzing quantitative and qualitative batch manufacturing data. Financial details around the acquisition were not disclosed, but Michael Felo, director of Integrated Solutions Marketing, BioContinuum Platform, at MilliporeSigma,…

Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy

GE Healthcare’s Biopharma business has announced plans to change its name and logo in anticipation of its acquisition by Danaher Corporation later this year. “On February 25 our lives changed,” Dodi Axelson, head of Communications, Life Sciences at GE Healthcare told Bioprocess Insider. She spoke, of course, about the agreement by Danaher Corporation to acquire the BioPharma portion of GE Healthcare’s Life Sciences business for a cash price of $21.4 billion (€19.4 billion). The deal is still under regulatory review…

Batavia selects CHO platform for Zika Ab on the Horizon

A collaboration led by Batavia Biosciences will use Horizon Discovery’s CHO cell technology in the development of an antibody against Zika. Batavia Biosciences, working with Vanderbilt University Medical Center (VUMC) and IDBiologics, is looking to develop a therapy based on a Zika virus neutralizing antibody that was discovered three years ago. Accessing Horizon Discovery’s GS knockout Chinese hamster ovary (CHO) K1 cell line expression system will allow the development of high yield antibody-expressing cell lines, Batavia CEO Menzo Havenga told…

Why freezing should be a hot topic for cell therapy sector

Cell therapy firms need to think about freezing earlier in process development according to an expert, who says optimized cryopreservation is key. Cell therapies have the potential to revolutionize medicine. For example, products like Yescarta and Kymriah can treat cancers more effectively and with fewer side effects than even the best chemotherapies. But unlike chemotherapies, cell therapies are highly susceptible to the temperature fluctuations that occur during transportation. To address this, developers protect their products using various methods, with cryopreservation…

Commercial N-1 perfusion carried out by Samsung BioLogics

CDMO Samsung BioLogics has used an Alternating Tangential Flow (ATF) system to perform N-1 perfusion at its 180,000 L facility in South Korea. Contract development and manufacturing organization (CDMO) Samsung BioLogics opened its number 3 facility at its site in Songdo, Incheon last year, boasting 180,000 L of commercial stainless steel bioreactor capacity. This month, the firm has announced it has successfully carried out N-1 perfusion with an Alternating Tangential Flow (ATF) system at the 3,000 L scale to supply…

From zero to $250m: Agilent aims to dominate cell analysis space

With potentially three acquisitions within nine months, Agilent Technologies has rapidly grown its presence in the cell analysis space and says it aspires to grow further. Technology and services firm Agilent entered the bioanalysis space in 2015 when it acquired manufacturer of instruments and assay kits Seahorse Bioscience. Over the past nine months, Agilent has upped its position in the sector through the purchase of ACEA Biosciences, swiftly followed by the acquisition of Luxcel Biosciences , and just last month…

Dyadic: Deals stack up as industry looks to ‘game-changing’ expression system

Another quarter of deal making by Dyadic International demonstrates how companies are looking to microorganisms instead of CHO to produce affordable drugs, the firm says. Numerous biopharma and biotech firms over the past few years have been turning to Dyadic International to access its C1 fungus-based expression system. The second quarter 2019 was no exception, with Luina Bio, Alphazyme, and the Serum Institute of India inking separate agreements with Dyadic within a two-week period. Such deals reflect Dyadic’s long-term vision…

Sartorius (cell) banks on mammalian manufacturing

Sartorius Stedim Biotech says its newly launched mammalian cell bank manufacturing offering fits hand-in-hand with its existing cell line development services. German bioprocess vendor Sartorius has grown its contract testing and manufacturing services over the past few years, not least through the acquisition of analytics and product characterization firm BioOutsource in 2015. Now the subsidiary Sartorius Stedim BioOutsource will offer the manufacture of GMP master and working cell banks (MCB/WCB) for mammalian suspension cells from its site in Glasgow, UK.…